2020-2027 Analysis and Review Flecainide Market

Flecainide Market

Flecainide Market By Indication (Supraventricular Tachycardia, Atrial Fibrillation, Wolff-Parkinson-White Syndrome and Others), By End User (Hospital Pharmacy, Retail Pharmacy and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027

22-02-2020 REP-HC-5038 40 Tables 113 pages Format

The flecainide market was valued at USD270.3 Mn by 2019. As per the research citings brought forward by the World Health Organization (WHO), cardiovascular complications are responsible for 17.9 million deaths which is equivalent to 31% of the deaths occurring throughout the globe. Lower costs associated with generic versions of flecainide and favorable reimbursement scenario together drive the flecainide market growth.

 Flecainide Market

Flecainide acetate gained approval form the USFDA in 1985 for the treatment of supraventricular arrhythmias and atrial flutter. It usually causes the inhibition of the action of potassium and sodium ion channels in the heart thereby increasing the threshold for depolarization and correcting arrhythmias. It is important to understand this drug has a very narrow therapeutic index and should not be prescribed in patients suffering from left ventricular systolic dysfunction. The drug posology for ventricular tachycardia is 100mg orally after every 12 hours and for atrial fibrillation, the dose is adjusted at 50mg after every 12 hours.

The major segments related to the flecainide market are:

By Indication (2017–2027; US$ Mn)

Supraventricular Tachycardia

Atrial Fibrillation

Wolff-Parkinson-White Syndrome

Others

By End User (2017–2027; US$ Mn)

Hospital Pharmacy

Retail Pharmacy

Others

Geography Segment(2017–2027; US$ Mn)

North America

United States
Canada

Europe

United Kingdom
Germany
Rest of Europe

Asia Pacific

China
Japan
Rest of Asia Pacific

Latin America (LATAM)

Brazil
Mexico
Rest of Latin America

Middle East and Africa (MEA)

GCC
Rest of MEA 

Justification for study?

  • The intention of the study is to give a comprehensive outlook of the global flecainide market
  • The overall segmentation of the flecainide market, by indication, end-user, and geography is minutely studied. Supraventricular tachycardia and hospital pharmacy are dominating the indication and end-user segments respectively
  • Significant rise in the cardiovascular and pulmonary disorders worldwide primarily determine the flecainide market growth
  • Constant rise in the generic market in the developing nations further propels the flecainide market growth

Report gist?

  • The study of the global flecainide market includes qualitative analysis of factors such as drivers, restraints, and opportunities
  • The report covers qualitative and quantitative analysis of the overall market segmented on the basis of indication and end-user and categorization of the same at geography level
  • This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. Compounded annual growth rate is calculated for the respective segments from 2020 to 2027
  • The study includes the profiles of major market players with a significant global and regional presence along with top company positioning

Significant customers?

  • This study is suitable for industry participants and stakeholders in the medical device manufacturers engaged in the manufacturing and marketing of flecainide for the treatment of cardio-pulmonary complications in geriatric population worldwide
  • The report will benefit cardiologist to prescribe flecainide to patients suffering from different forms of cardiac arrhythmia
  • Managers with financial institutions looking to publish recent and forecasted statistics pertaining to flecainide market
  • Financial institutions venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies 

Segment Analysis

In the present scenario, supraventricular tachycardia is spearheading the indication segment for the flecainide market. As per the statistics presented by the World Health Organization (WHO), the global incidence rate of supraventricular tachycardia is 35 per 100,000 people, the most common type of supraventricular tachycardia that occurs in women and older adults is the paroxysmal supraventricular tachycardia. The chief causative agent is the existing conditions of heart failure and congenital heart defects. The Wolff-Parkinson-White syndrome is anticipated to register rapid market growth owing to the constant rise in the newborn suffering with Ebstein anomaly which is manifested by the structural defect of the tricuspid valve which allows the blood to flow from the right atrium to right ventricles.

Hospital pharmacy is currently dominating the end-user segment for the flecainide market. The chief contributing factors responsible for its positive market growth are the availability of skilled pharmacists to compound flecainide drug I different dose requirements depending on the severity of cardiac arrhythmias in patients admitted in hospitals and cardiac research centers worldwide. Retail pharmacy is growing at an exponential rate in the developing nations owing to the presence of a huge generic market and its capability to serve the medical needs of cardiac patients residing in far-flung remote areas.

North America is considered as the largest shareholder in the geography for the flecainide market. As per the latest research citings brought forward by the American College of Cardiology (ACC) approximately 5.3 million people in the United States suffer from atrial fibrillation. Rising prevalence of cardiovascular complications and the existence of well-developed healthcare infrastructure buttress the flecainide market growth in North America. Domicile of key players such as Mylan Labs Ltd., Aurobindo Pharma, Amneal Pharmaceuticals, LLC., Apotex, Inc., etc., further consolidates the market growth in the region. The market growth in Europe is primarily determined by the affordable reimbursement scenario associated with the use of flecainide for the treatment of cardiac arrhythmias occurring in the geriatric population. The constant rise in the number of Wolff-Parkinson-White Syndrome in the Eastern European Region further provides a positive impetus to flecainide market growth. Asia Pacific is set to witness rampant market growth in the near future owing to the significant rise in the medical tourism industry and the presence of booming generic medicines market in the region.

Select License Type

$4,600
$6,600
$9,500

Safe and Secure SSL Encrypted

Have a Question?

We will help you find what you are looking for.

Call 1-518-730-1560

Contact sales

How can we help you?

Get in touch with us or find an office closest to you.